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To the Editor: The Timing of Intervention in 
Acute Coronary Syndrome (TIMACS) trial report-
ed on by Mehta et al. (May 21 issue)1 showed that 
a routine early-intervention strategy was not su-
perior to a delayed-intervention strategy for the 
prevention of the composite primary outcome of 
death, myocardial infarction, or stroke. There was 
no evidence of an early hazard associated with 
early intervention. The authors consider a poten-
tially important finding that in a prespecified sub-
group of high-risk patients, early intervention 
appeared to provide a significant benefit, main-
ly due to an increased accumulation of events in 
the delayed-intervention group from 30 days to 
6 months after randomization. This is a striking 
observation, since the percentage of patients who 
underwent angiography and subsequent revascu-
larization per protocol was virtually similar at 30 
days in both groups. The authors do not address 
this finding and do not provide us with an expla-
nation of this difference in the late accumulation 
of events. Therefore, we contend that this could 
be a spurious finding due to a subgroup analysis, 
albeit prespecified, in which the overall primary 
outcome of the TIMACS trial was negative.
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To the Editor: Mehta et al. do not show any 
significant difference between early and delayed 
intervention in patients with acute coronary syn-
drome. In their study, 9.9% of patients in the 
early-intervention group received intervention 
more than 24 hours after randomization and 
20.5% of patients in the delayed-intervention group 
received intervention less than 36 hours after 
randomization. The authors used an intention-
to-treat principle for their analysis. One of the 
limitations of intention-to-treat analysis is that 
interpretation becomes difficult if large propor-
tions of patients cross over to the opposite treat-
ment groups.1 Although there was no actual cross-
over in this study, it would be interesting to note 
whether any difference between the two groups 
would be present if a treatment-received analysis 
was used to estimate the difference between the 
two groups. It would also be interesting to note 
the risk profile and average time of intervention 
among patients who did not receive intervention 
as per protocol to see whether this was the reason 
the study did not show any significant result.
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To the Editor: In their editorial, Hillis and 
Lange1 report that low-risk patients should receive 
unfractionated heparin for 2 to 5 days. However, 
unfractionated heparin has pharmacologic limi-
tations that may affect efficacy and safety. Fre-
quent monitoring of activated partial-thrombo-
plastin time is necessary to achieve optimal 
anticoagulation levels. Enoxaparin and fonda-
parinux are options for anticoagulation with ei-
ther superior efficacy2 or better safety3 and with 
a different pharmacodynamic profile than un-
fractionated heparin. As compared with unfrac-
tionated heparin, enoxaparin has greater bioavail-
ability, providing a more stable and predictable 
anticoagulation, and fondaparinux has a more 
favorable tolerability, particularly regarding the 
risk of major bleeding. Both allow fixed dosing 
without the need for monitoring, and they facili-
tate a longer duration of treatment. Furthermore, 
both regimens are class I recommendations in the 
American College of Cardiology–American Heart 
Association (ACC–AHA) guidelines for patients 
in whom a conservative strategy is selected.4
In addition, although Hillis and Lange recom-
mend the discontinuation of anticoagulation 
treatment in high-risk patients after successful 
percutaneous coronary intervention (PCI), they 
suggest the use of glycoprotein IIb/IIIa inhibi-
tion for 12 to 24 hours after PCI. What is the 
current rationale for this recommendation?
Angel Cequier, M.D., Ph.D. 
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To the Editor: Hillis and Lange summarize the 
evidence-based treatment strategies for patients 
with acute coronary syndrome. However, they do 
not mention the role of angiotensin-converting–
enzyme (ACE) inhibitors, which have been rec-
ommended by the ACC–AHA joint guidelines for 
the treatment of patients with unstable angina 
and non–ST-elevation myocardial infarction1 and 
by the European Society of Cardiology guidelines 
for the diagnosis and treatment of non–ST-seg-
ment elevation acute coronary syndrome.2 Both 
sets of guidelines strongly recommend (level of 
evidence A, class I) that ACE inhibitors should be 
initiated during the course of hospitalization in 
patients with diabetes, hypertension, or a left ven-
tricular ejection fraction of less than 40%; these 
recommendations are not as strong for all other 
patients (level of evidence A, class IIa).
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The Authors Reply: We agree with Damman et 
al. that subgroup analyses should be interpreted 
with caution. The prespecified analysis in the 
TIMACS trial that showed a greater benefit of 
early intervention in patients at high risk is sup-
ported by a statistically significant test for inter-
action (P = 0.01), which is a relatively stringent test. 
Damman et al. incorrectly suggest that the ben-
efit of early intervention in the high-risk patients 
was mainly due to a late accumulation of events. 
As early as 1 week after randomization, there was 
an emerging benefit of the early invasive strategy 
in patients at high risk (5.8% in the early-inter-
vention group vs. 8.0% in the delayed-interven-
tion group; hazard ratio, 0.73; 95% confidence 
interval [CI], 0.45 to 1.18), with no apparent dif-
ference in outcomes in the group at low-to-inter-
mediate risk (3.5% in the early-intervention group 
vs. 3.3% in the delayed-intervention group; haz-
ard ratio, 1.08; 95% CI, 0.68 to 1.73). Moreover, a 
similar finding of a greater benefit in high-risk 
patients was also observed in the secondary out-
come of death, myocardial infarction, or refrac-
tory ischemia.
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In response to Rathod: TIMACS was a prag-
matic effectiveness trial designed to evaluate two 
management strategies, and an intention-to-treat 
approach is the correct method to analyze the 
results of such trials.1,2 Performance of clini-
cally indicated early intervention for valid, proto-
col-defined reasons in patients randomly assigned 
to the delayed strategy was an integral compo-
nent of that strategy, and it would not be appro-
priate to exclude such patients. Moreover, a 
“treatment-received” analysis, as Rathod sug-
gests, is flawed because it introduces bias that 
invalidates the essential value of randomization 
by excluding persons on the basis of a differing 
clinical course after randomization.1,2 Finally, the 
protocol-defined criteria for crossover (i.e., new 
myocardial infarction, hemodynamic instability 
with a high risk of death, and refractory ische-
mia) included components of the primary or sec-
ondary outcome and thus are already reflected 
in the main results of the trial. For these rea-
sons, we believe that a treatment-received analy-
sis would not be helpful in interpreting the re-
sults of the trial.
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The Editorialists Reply: We agree with Cequier 
et al. that unfractionated heparin has limitations. 
However, in patients with acute coronary syn-
drome who are considered to be at low risk for a 
cardiac event, unfractionated heparin and enox-
aparin have similar efficacy in preventing death 
and myocardial infarction,1 and the former is 
much less expensive than the latter. Although the 
systematic review by Petersen et al.2 suggests 
that the use of enoxaparin is associated with a 
modest reduction in nonfatal myocardial infarc-
tion and no difference in mortality as compared 
with unfractionated heparin, the trial populations 
in the review were not identical with respect to 
their baseline characteristics, in that, by design, 
the later trials included higher-risk patients. 
Fondaparinux has not received approval by the 
Food and Drug Administration for the treatment 
of patients with acute coronary syndromes, and 
its safety and efficacy in patients undergoing PCI 
are not well established.3 After successful PCI, 
discontinuation of anticoagulant therapy is rec-
ommended, since its continued use offers no 
proven benefit in further reducing cardiac events 
and is associated with increased bleeding, particu-
larly at the site of catheterization. In contrast, 
therapy with a glycoprotein IIb/IIIa inhibitor is 
ineffective in reducing cardiac events if it is dis-
continued immediately after PCI4; as a result, 
continued infusion for 12 to 24 hours is recom-
mended.
As Shojai notes, the evidence supporting the 
use of ACE inhibitors in patients with acute cor-
onary syndromes and concomitant pulmonary 
congestion or left ventricular systolic dysfunc-
tion (ejection fraction, ≤0.40) in the absence of 
hypotension or known contraindications to these 
agents is strong. In addition, the benefits of ACE 
inhibitors in improving ischemic outcomes have 
been the subject of study in patients with stable 
coronary artery disease. However, since ACE in-
hibitors have not been tested directly in patients 
with acute coronary syndromes, we chose not to 
recommend their routine use.
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